These molecules likely contribute to anti‐tumour immunity through distinct mechanisms—CD40 by enhancing dendritic cell activation and cytotoxic T cell responses, and CCL4 by potentially recruiting anti‐tumour immune cells to the tumour microenvironment. This evidence concerns the gene CCL4 and neoplasm.